These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 27561974)

  • 21. Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patients.
    Le Moulec S; Hadoux J; Gontier E; Chargari C; Helissey C; Lamand V; Tanz R; Farace F; Vedrine L; Bonardel G; Soria JC; Besse B
    Bull Cancer; 2013 Dec; 100(12):30-7. PubMed ID: 24316967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734.
    Perry MC; Kohman LJ; Bonner JA; Gu L; Wang X; Vokes EE; Green MR
    Clin Lung Cancer; 2007 Jan; 8(4):268-72. PubMed ID: 17311692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
    Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
    Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer.
    Decatris MP; O'Byrne KJ
    Future Oncol; 2016 Aug; 12(15):1805-22. PubMed ID: 27267211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Durable Response After 2 Doses of Pembrolizumab in a Patient With Non-Small-Cell Lung Cancer With an Isolated Brain Metastasis.
    Uprety D; Arjyal L; Vallatharasu Y; Bista A; Wittchow RJ; Marinier DE
    Clin Lung Cancer; 2019 Sep; 20(5):e552-e554. PubMed ID: 31285178
    [No Abstract]   [Full Text] [Related]  

  • 26. A phase II trial of preoperative concurrent radiation therapy and weekly paclitaxel/carboplatin for patients with locally advanced non-small-cell lung cancer.
    Hainsworth JD; Gray JR; Litchy S; Bearden JD; Shaffer DW; Houston GA; Greco FA
    Clin Lung Cancer; 2004 Jul; 6(1):33-42. PubMed ID: 15310415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?
    D'Argento E; Rossi S; Schinzari G; Strippoli A; Basso M; Cassano A; Barone C
    Curr Treat Options Oncol; 2016 Dec; 17(12):59. PubMed ID: 27766545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
    Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
    Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer.
    Qin A; Street L; Cease K; Viglianti BL; Warren EH; Zhao L; Ramnath N
    Clin Lung Cancer; 2017 Sep; 18(5):559-564. PubMed ID: 28366756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Local therapy combined with anti-PD-1 immunotherapy for advanced lung adenocarcinoma: A case report.
    Wu N; Yang X; Zhai Y; Lu W
    J Cancer Res Ther; 2024 Apr; 20(2):739-744. PubMed ID: 38687948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Weekly paclitaxel and carboplatin with concurrent three dimensional conformal radiotherapy for locally advanced non small cell lung cancer].
    Wang J; Pang QS; Wang P; Wang J; Wang W
    Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):769-72. PubMed ID: 18396691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Ipilimumab and metastatic lung cancer: Can we change the natural history of the disease?].
    Boyer A; Greillier L; Barazzutti H; Tomasini P; Barlesi F
    Rev Mal Respir; 2015 Nov; 32(9):949-52. PubMed ID: 25725978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management].
    Basse C; Swalduz A; Levra MG; Girard N; Remon J; Moro-Sibilot D
    Bull Cancer; 2020; 107(7-8):779-791. PubMed ID: 32532420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report.
    Li D; He C; Xia Y; Du Y; Zhang J
    J Med Case Rep; 2018 Apr; 12(1):104. PubMed ID: 29681240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer.
    Yuanying Y; Lizhi N; Feng M; Xiaohua W; Jianying Z; Fei Y; Feng J; Lihua H; Jibing C; Jialiang L; Kecheng X
    Cryobiology; 2013 Oct; 67(2):235-40. PubMed ID: 23948179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel immunotherapy in the treatment of advanced non-small cell lung cancer.
    Santabarbara G; Maione P; Rossi A; Palazzolo G; Gridelli C
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1571-1581. PubMed ID: 27623999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune checkpoint therapy for non-small-cell lung cancer: an update.
    Xia B; Herbst RS
    Immunotherapy; 2016; 8(3):279-98. PubMed ID: 26860624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA approves breakthrough immunotherapy for patients with non-small-cell lung cancer.
    Printz C
    Cancer; 2017 Jan; 123(2):191. PubMed ID: 28067949
    [No Abstract]   [Full Text] [Related]  

  • 39. How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care.
    Kris MG
    Oncologist; 2005 Oct; 10 Suppl 2():23-9. PubMed ID: 16272456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer.
    Heigener D; Reck M
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):69-83. PubMed ID: 25199617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.